Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13828543 | 0.82 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL2743303 | 0.82 | EGLN1 (0.37) | ALDH1A1HCAR2SMN1; SMN2MAPTPIN1 | |
| SCHEMBL10772488 | 0.78 | HCAR2 (0.34) | ALDH1A1HCAR2SMN1; SMN2MAPTPIN1 | |
| SCHEMBL10775641 | 0.78 | CYP1A2 (0.38) | ALDH1A1HCAR2SMN1; SMN2MAPTKDM4E | |
| SCHEMBL10773190 | 0.78 | ALDH1A1 (0.34) | ALDH1A1HCAR2SMN1; SMN2MAPTPIN1 | |
| SCHEMBL10177617 | 0.75 | TDP1 (0.41) | ALDH1A1HCAR2PIN1KDM4EPOLB | |
| SCHEMBL16963172 | 0.75 | MEN1 (0.46) | ALDH1A1HCAR2SMN1; SMN2KDM4E | |
| SCHEMBL13544390 | 0.75 | HPGD (0.40) | ALDH1A1SMN1; SMN2KDM4EPOLBGAA | |
| SCHEMBL4266121 | 0.74 | — | — | |
| SCHEMBL18305810 | 0.73 | ALDH1A1 (0.39) | ALDH1A1HCAR2SMN1; SMN2MAPTPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9801888-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2017-10-31 | — | — | US | disclosed |
| US-20160136176-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-05-19 | — | — | US | disclosed |
| US-9315491-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-04-19 | — | — | US | disclosed |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | ALDH1A1 2963/4885HCAR2 3211/4885SMN1; SMN2 3386/4885 |
| US-20160136176-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | ALDH1A1 2963/4885HCAR2 3211/4885SMN1; SMN2 3386/4885 |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | ALDH1A1 2963/4885HCAR2 3211/4885SMN1; SMN2 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.